glucose, (beta-d)-isomer has been researched along with Respiratory Syncytial Virus Infections in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Curtis, C; Dubovsky, F; Ervin, J; Esser, MT; Falloon, J; Krieger, D; Lambert, SL; Takas, T; Talbot, HK; Villafana, T; Yu, J; Yu, L | 1 |
| Dubovsky, F; Esser, MT; Falloon, J; Falsey, AR; Levin, MJ; Takas, T; Villafana, T; Yu, J; Yu, L | 1 |
| Bart, S; Curtis, C; Dubovsky, F; Esser, MT; Falloon, J; Ji, F; Krieger, D; Lambert, S; Sheldon, E; Takas, T; Villafana, T | 1 |
3 trial(s) available for glucose, (beta-d)-isomer and Respiratory Syncytial Virus Infections
| Article | Year |
|---|---|
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; Antibodies, Viral; Dose-Response Relationship, Immunologic; Double-Blind Method; Enzyme-Linked Immunospot Assay; Female; Glucosides; Humans; Immunity, Cellular; Immunity, Humoral; Immunogenicity, Vaccine; Immunoglobulin G; Influenza Vaccines; Influenza, Human; Interferon-gamma; Lipid A; Male; Middle Aged; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Vaccines; Respiratory Syncytial Virus, Human; T-Lymphocytes; Viral Fusion Proteins | 2017 |
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Aged; Antibodies, Neutralizing; Antibodies, Viral; Antibody Formation; Antigens, Bacterial; Antigens, Viral; Double-Blind Method; Female; Glucosides; Humans; Immunoglobulin G; Influenza Vaccines; Lipid A; Male; Middle Aged; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Vaccines; Respiratory Syncytial Virus, Human; Viral Fusion Proteins | 2017 |
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antibodies, Neutralizing; Antibodies, Viral; Double-Blind Method; Emulsions; Female; Glucosides; Humans; Immunity, Cellular; Immunity, Humoral; Immunoglobulin G; Lipid A; Male; Middle Aged; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Vaccines; Respiratory Syncytial Virus, Human; Toll-Like Receptor 4; Viral Fusion Proteins | 2016 |